[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].

Abstract

BACKGROUND The combination of modern systemic chemotherapy and anti-EGFR monoclonal antibodies improves overall survival and quality of life for patients with metastatic colorecal cancer. By contrast, the addition of anti-EGFR therapy to the treatment regime of resistant patients may lead to worse progression-free survival and overall survival. Therefore… (More)

Topics

  • Presentations referencing similar topics